SavedAdd your journal

Journals / Glokom Katarakt / 2010 / Cilt: 5 - Sayı: 4

Monotherapy in glaucoma

Glokomda monoterapi

Oya TEKELİ
Pages
186–188
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review aims to discuss monotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glaucoma, a chronic optic neuropathy, is characterized by a progressive loss of the retinal nerve fiber layer and visual field defects.
📊
Key Findings & Data:Reduction of IOP is the most efficient and clinically accepted therapy.
💡
Conclusion & Impact:This review aims to discuss monotherapy.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Glaucoma, a chronic optic neuropathy, is characterized by a progressive loss of the retinal nerve fiber layer and visual field defects. Reduction of IOP is the most efficient and clinically accepted therapy. Topical medications for lowering IOP have shown good efficacy and safety in glaucoma. It is known that inadequate compliance with glaucoma therapy is a risk factor for progression of the disease. Monotherapy has some clear advantages for the treatment of glaucoma. This review aims to discuss monotherapy.

Özet

Kronik bir optik nöropati olan glokom, retina sinir lifi tabakasının ilerleyici kaybı ve görme alanı defektleri ile karakterizedir. Göz içi basıncının (GİB) azaltılması en etkin ve klinik olarak kabul edilen bir tedavidir. Glokomda GİB'nı düşürmek için topikal tedavinin etkin ve emniyetli olduğu gösterilmiştir. Glokom tedavisine olan yetersiz uyum hastalığın ilerlemesi için bir risk faktörüdür. Glokom tedavisinde monoterapi bazı avantajlara sahiptir. Bu yazıda monoterapinin tartışılması amaçlanmıştır.

🔖

Cite This Article

TEKELİ, O. (2010). Monotherapy in glaucoma. Glokom Katarakt, Cilt: 5 - Sayı: 4, 186–188. https://ajindex.com/articles/226540

References (1)

  1. Crichton A, Drance SM, Douglas GR, et al.: Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma. Ophthalmology. 1989;96:1312-1314. 2.Leskea MC, Heijl A, Hymann L, et al.: Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol. 2004;15:102-106. 3.Medical Treatment of Glaucoma.: Selection of drugs. ln:Weinreb RW, Liebmann J, eds. Kugler publications, Amsterdam, The Netherlands. 2010;131 -138. 4.Friedman DS, Qigley HA, Gelb L, et al.: Compliance and persistency in glaucoma follow-up treatment. Invest Ophthalmol Vis Sci. 2007;48:5052-5057. 5.Popovic Suic S, Cerovski B, Jukic T.: The role of patient compliance in the management of glaucoma. Acta Med Croatica. 2008;62:57-59. 6.Terminology and Guidelines for glaucoma third edition 7.Aim A, Grierson I, Shields MB.: Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53:93-105. 8.Liu JH, Medeiros FA, Rigby SL, et al.: Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology. 2009;116:449-454. 9.Sit A, Asrani S.: Effects of medications and surgery on intraocular pressure fluctuation. Surv Ophthalmol. 2008;53:45-55. 10.Orzalesi N, Rossetti L, Invernizzi T, et al.: Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566-2573. 11.Aktaş Z, Gürelik G, Akyürek N, et al.: Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model. Clin Experiment Ophthalmol. 2007;35:527-534. 12.Harris A, Migliardi R, Rechtman E, et al.: Comparative analysis of the effects of dorzolamide and latanoprost on ocular hemodynamics in normal tension glaucoma patients Eur J Ophthalmol. 2003;13:24-31. 13.Siesky B, Harris A, Cantor LB, et al.: A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br J Ophthalmol. 2008;92:500-504. 14.Harris A, Arend O, Kagemann L, et al.: Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J Ocul Pharmacol Ther. 1999;15:189-197. 15.lester M, Altieri M, Michelson G, et al.: Retinal peripapillary blood flow before and after topical brinzolamide. Ophthalmologica. 2004;218:390-396.